Authors : Manoj S , Sameer Iqbal, Narendra Meel, Unnikrishnan Nair
DOI : 10.18231/j.ijceo.2022.105
Volume : 8
Issue : 4
Year : 2022
Page No : 520-524
Purpose: To evaluate and compare the efficacy of reduced-fluence photodynamic therapy (PDT) with standard-fluence photodynamic therapy in treating polypoidal choroidal vasculopathy.
Materials and Methods: Twenty-eight eyes (27 patients) with polypoidal choroidal vasculopathy were retrospectively analysed; 14 eyes received Indocyanine green angiography-guided standard-fluence (SF) PDT (50 J/cm) and 14 eyes received Indocyanine green angiography-guided reduced-fluence (RF) PDT (25 J/cm). Primary outcome measured after 6 months of treatment were the changes in mean BCVA, polyp regression, polyp PED height, central choroidal thickness (CCT), post PDT intravitreal anti VEGF injection need and complications.
Results: Results of both the groups were comparable at 6 months follow up. Mean change in log mar visual acuity at 6 months for the SF PDT group was 0.12 compared to 0.13 for the RF PDT group (p?=?0.919). Mean change in PED height at 6 months for the SF PDT group was 159 ?m compared to 172 ?m for the RF PDT group (p?=?0.06). Mean change in CCT at 6 months for the SF PDT group was 45?m compared to 10?m for the RF PDT group (p?=?0.96). While the SF PDT group needed a mean of 2 injections post PDT, the RF PDT group required a mean of 3 injections during the course of 6 months follow up. Neither of the group reported any adverse effects following the procedure.
Conclusions: Our study demonstrated that reduced-fluence PDT is at least on par with standard-fluence PDT in management of PCV.
Keywords: Polypoidal choroidal vasculopathy, Photodynamic therapy, Reduced fluence PDT, Standard fluence PDT.